2 completed, 1 terminated. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Phase 2 | 1 | Completed 1 |
Follow MK-8776: new trials by email Literature Review of MK-8776 trials Research Report on MK-8776
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia Cytarabine, CHK1 Inhibitor SCH 900776, Laboratory Biomarker Analysis - Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia | Phase 2 | Completed | National Cancer Institute (NCI) | 32 | 2013-05-01 | 2016-09-01 |
| Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247) MK-8776, Cytarabine - Myelogenous Leukemia, Acute, Leukemia, Lymphocytic, Acute | Phase 1 | Terminated | Merck Sharp & Dohme LLC | 24 | 2009-07-29 | 2018-08-27 |
| A Dose-escalation Study of MK-8776 (SCH 900776) With and Without Gemcitabine in Participants With Solid Tumors or Lymphoma (MK-8776-002/P05248) MK-8776, Gemcitabine - Hodgkin Disease, Lymphoma, Non-Hodgkin | Phase 1 | Completed | Merck Sharp & Dohme LLC | 45 | 2008-10-17 | 2018-08-27 |
Leukemia, Myeloid, Acute (2) · Hodgkin Disease (1) · Leukemia, Erythroblastic, Acute (1) · Leukemia, Megakaryoblastic, Acute (1) · Leukemia, Monocytic, Acute (1) · Leukemia, Myeloid, Accelerated Phase (1) · Leukemia, Myelomonocytic, Acute (1) · Lymphoma, Non-Hodgkin (1) · Neoplasms (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Merck Sharp & Dohme LLC (2) · National Cancer Institute (NCI) (1)
United States (1)
B. Smith (1)
P30CA006973 (1), U01CA070095 (1)